Positive results for Cimzia in moderate-to-severe chronic plaque psoriasis

Belgium’s largest drugmaker UCB (Euronext: UCB) and Dermira (Nasdaq: DERM) have said they expect to file for regulatory approval later this year of their anti-inflammatory drug following the latest positive clinical trial results.

The companies today announced key results from CIMPACT, a Phase III, multicenter, placebo-controlled and active-controlled clinical trial evaluating the efficacy and safety of Cimzia (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis.

In the CIMPACT trial, Cimzia demonstrated statistically significant improvements for the primary endpoint. CIMPACT is the third and final Phase III clinical trial evaluating Cimzia in this patient population. Based on the results of the CIMPACT trial, and those from the previously reported CIMPASI-1 and CIMPASI-2 trials, UCB intends to submit marketing applications to regulatory authorities in the third quarter of 2017.